Availability, price and affordability of cardiovascular medicines: A comparison across 36 countries using WHO/HAI data
Open Access
- 9 June 2010
- journal article
- research article
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 10 (1) , 25
- https://doi.org/10.1186/1471-2261-10-25
Abstract
The global burden of cardiovascular disease (CVD) continues to rise. Successful treatment of CVD requires adequate pharmaceutical management. The aim was to examine the availability, pricing and affordability of cardiovascular medicines in developing countries using the standardized data collected according to the World Health Organization/Health Action International methodology.Keywords
This publication has 12 references indexed in Scilit:
- Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysisPublished by Elsevier ,2008
- Retail prices of essential drugs in Brazil: an international comparison.Revista Panamericana de Salud Pública, 2007
- The availability and affordability of selected essential medicines for chronicl diseases in six low- and middle-income countriesPublished by WHO Press ,2007
- Projections of Global Mortality and Burden of Disease from 2002 to 2030PLoS Medicine, 2006
- WHO study on Prevention of REcurrences of Myocardial Infarction and StrokE (WHO-PREMISE).2005
- Unaffordable drug prices: the major cause of non-compliance with hypertension medication in Ghana.2004
- Disponibilidade de medicamentos essenciais em duas regiões de Minas Gerais, BrasilRevista Panamericana de Salud Pública, 2004
- Two decades of progress in preventing vascular diseaseThe Lancet, 2002
- Global Burden of Cardiovascular DiseasesCirculation, 2001
- Changes in the Costs of Antihypertensive Medications in a Developing Country A Study in Mexico Comparing 1990 and 1996American Journal of Hypertension, 1998